Company profile for Plus Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

PLUS THERAPEUTICS is a clinical-stage pharmaceutical company focused on making a positive impact on patients’ lives and adding value to the healthcare system. We are a publicly-traded company on Nasdaq (PSTV, an abbreviation of ‘POSITIVE’) with our headquarters in Austin, Texas and GMP-validated manufacturing facilities in San Antonio, Texas. The location of our operations provides us with many potential strategic advan...
PLUS THERAPEUTICS is a clinical-stage pharmaceutical company focused on making a positive impact on patients’ lives and adding value to the healthcare system. We are a publicly-traded company on Nasdaq (PSTV, an abbreviation of ‘POSITIVE’) with our headquarters in Austin, Texas and GMP-validated manufacturing facilities in San Antonio, Texas. The location of our operations provides us with many potential strategic advantages, including proximity to world-class cancer institutions and researchers and the ability to qualify and apply for funding through the Cancer Prevention and Research Institute of Texas, or CPRIT.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
4200 Marathon Blvd., Suite 200 Austin, TX 78756 USA
Telephone
Telephone
+1.737.255.7194
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/11/3203802/0/en/Plus-Therapeutics-Expands-CNSide-Assay-Platform-to-State-of-California.html

GLOBENEWSWIRE
11 Dec 2025

https://www.globenewswire.com/news-release/2025/12/09/3202254/0/en/Plus-Therapeutics-Announces-Expansion-of-CNSide-Team-and-Issuance-of-Inducement-Grants.html

GLOBENEWSWIRE
09 Dec 2025

https://www.globenewswire.com/news-release/2025/12/01/3196910/0/en/Plus-Therapeutics-to-Present-ReSPECT-Phase-1-Dose-Escalation-Study-Results-for-Leptomeningeal-Metastases-at-the-2025-San-Antonio-Breast-Cancer-Symposium.html

GLOBENEWSWIRE
01 Dec 2025

https://www.globenewswire.com/news-release/2025/11/24/3193399/0/en/Plus-Therapeutics-Announces-Completion-of-U-S-FDA-Meeting-on-Future-Clinical-Development-Plans-for-REYOBIQ-in-Leptomeningeal-Metastases.html

GLOBENEWSWIRE
24 Nov 2025

https://www.globenewswire.com/news-release/2025/11/20/3191797/0/en/Plus-Therapeutics-Secures-National-Coverage-Agreement-with-Humana-for-CNSide-Cerebrospinal-Fluid-Assay-for-Metastatic-CNS-Cancer.html

GLOBENEWSWIRE
20 Nov 2025

https://www.globenewswire.com/news-release/2025/11/17/3189010/0/en/Plus-Therapeutics-Granted-180-Day-Extension-to-Regain-Compliance-with-Nasdaq-s-Minimum-Bid-Price-Requirement.html

GLOBENEWSWIRE
17 Nov 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty